Trial snapshot
- Formal name: Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses (MCW I-PREDICT)
- Trial type: Includes fibrolamellar carcinoma (precision oncology)
- Phase: Phase I / II
- Recruitment status: Active, Recruiting
- Eligible ages: 18 years and older
- Location: Milwaukee, WI (Medical College of Wisconsin)
- ClinicalTrials.gov ID: NCT05674825
Overview
This phase I/II study is designed to learn more about personalized cancer therapy, the practice of making decisions about what kind of treatment patients should receive based on the specific characteristics of their tumor. The study will evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized trial.
If not already performed, enrolled patients will have the molecular profiles of their tumor tissues/blood assessed. Based on “multi-omic” profiling, a matched therapy, if available, will be recommended by the study’s Molecular Tumor Board.
Trial details
The principal Investigators for the effort are Ben George, MD and Razelle Kurzrock, MD of the Medical College of Wisconsin.
For more information and the details, visit: https://clinicaltrials.gov/study/NCT05674825
Trial contact information
- MCW Clinical Trials Office – 414-805-8900
Please visit clinicaltrials.gov for a comprehensive list of active trials.
The Fibrolamellar Cancer Foundation does not provide medical advice. We provide website users with information to help them better understand their health conditions and current approaches towards diagnosis, treatment and supportive care. Always seek the advice of your physician or other qualified healthcare provider.